The multidrug transporter P-glycoprotein (Pgp), which is frequently overexpressed in multidrug resistant leukemia, has many proposed physiological functions including involvement in transmembraneous transport of certain growth-regulating cytokines. Therefore, we studied cell growth of three pairs of drug resistant and sensitive leukemia cell lines (KG1a, K562 and HL60) exposed to three different inhibitors of Pgp. The resistant KG1a and K562 sublines, which expressed high levels of Pgp, responded to low doses of the cyclosporin SDZ PSC 833, the cyclopeptolide SDZ 280-446, and the cyclopropyldibenzosuberane LY335979 with a dose-dependent growth inhibition. In the resistant variants of KG1a and K562 cells the mean half-maximal growth inhibitory doses (GI 50 ) of SDZ PSC 833 were 312 (SE 41) and 414 (SE 50) nM, those of SDZ 280-446 were 685 (SE 51) and 578 (SE 54) nM, and those of LY335979 were 66 (SE 1) and 48 (SE 8) nM, respectively. Exposure to 1 M SDZ PSC 833 resulted in tetraploidization, cytokinesis failure and apoptosis of the KG1a and K562 MDR variants. Conversely, parental cells with no or low levels of Pgp and the non-Pgp resistant variant of HL60 cells were not receptive to these cytotoxic effects. We conclude that inhibition of Pgp may exercise selective cytotoxicity in Pgp-rich leukemia cells indicating a possible therapeutic target in multiresistant leukemia.
Introduction
Failure to achieve complete and durable responses from cancer chemotherapy is a common clinical problem that limits the curative potential of anti-cancer drugs in clinical oncology. Multidrug resistance (MDR) is believed to be a major cause for treatment failure, and is frequently associated with overexpression of the multidrug transporter, P-glycoprotein (Pgp), which is an integral plasma membrane protein capable of drug expulsion and maintenance of tolerable intracellular levels of certain cytotoxic drugs. 1 Several clinically important anti-cancer drugs may be removed from neoplastic cells by Pgp-mediated transport, despite the diversity in chemical structures and mechanisms of action. 2 This ability is apparently reflected in a negative correlation between Pgp expression and chemosensitivity or survival in leukemias, 3, 4 lymphomas 5 and some solid tumors. [6] [7] [8] Pgp has a broad specificity for substrates, and several noncytotoxic drugs may competitively inhibit efflux of cytotoxic drugs by Pgp and thereby downmodulate MDR. 9 The calcium channel blocker verapamil was the first agent that was shown to modify MDR in vivo and in vitro, 10 but unfortunately the MDR modulating activity required concentrations that are associated with severe cardiac toxicity in patients. 11 Therefore, a new generation of highly specific and potent Pgp Correspondence: G Lehne, Department of Clinical Pharmacology, Rikshospitalet, The National Hospital of Norway, N-0027 Oslo; Fax: 47 22 11 19 87 Received 28 September 1998; accepted 28 December 1998 inhibitors with less toxic potential have been developed including the non-immunosuppressive cyclosporin SDZ PSC 833, 12 the cyclopeptolide SDZ 280-446, 13 and the cyclopropyldibenzosuberane LY 335979.
14 These agents exercise high affinity for Pgp and interfere with binding of known substrates such as azidopine and calcein. [15] [16] [17] SDZ PSC 833 which is the most extensively studied of these, has proven to be well tolerated in phase I trials, [18] [19] [20] and is currently being investigated as an adjunct to cancer chemotherapy in phase II and III trials.
Although Pgp contributes to renal and hepatic elimination of toxic compounds, 21 adrenal secretion of steroid hormones 22 and tissue protection at the blood-brain barrier, 23 the physiological role of Pgp is not fully understood. Two recent reports have shown that Pgp may also take part in the transport of growth stimulating cytokines IL-2 and IL-4. 24, 25 Thus, the participation of Pgp in growth regulation could represent a new target for growth control in neoplastic cells expressing Pgp. Recently, we discovered a selective cytotoxic effect of SDZ PSC 833 which engaged apoptosis (programmed cell death) in multidrug resistant leukemia cells. 26 As this effect appeared to involve Pgp, the present paper addresses the effect of other modulators on both Pgp-and non-Pgp-expressing leukemia cells, and further focuses on the induction of apoptosis in relation to cell cycle progression. The cells were characterized with respect to MDR phenotype and expression of proteins involved in the promotion (p53, Bax, Apol/Fas) and suppression (Bcl-2, Bcl-xL) of apoptosis. Pgp overexpression was the only common denominator which was exclusively associated with a dose-dependent growth inhibitory response to the modulators SDZ PSC 833, SDZ 280-446, and LY335979. Furthermore, the KG1a and K562 MDR variants, which shared these characteristics, also demonstrated attributes of cytokinesis failure and apoptosis after exposure to the modulators.
Materials and methods

Chemicals
The human leukemia cell lines were propagated in RPMI 1640 medium with l-glutamine (BioWhittaker, Walkersville, MA, USA) supplemented with 10% fetal calf serum, streptomycin (100 g/ml), penicillin (100 U/ml), nystatin (40 U/ml) and HEPES (only K562 cell lines). MRK16 was kindly provided by Professor T Tsuruo (Institute of Molecular and Cellular Biosciences, The University of Tokyo, Japan), and UIC2 was provided by Immunotech (Marseille, France). MRPr1 was a gift from Dr MJ Flens and Professor RJ Scheper (Department of Pathology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands). The IgG2a isotypic control antibody MOUSE IgG2a was purchased from Monosan (Uden, The Netherlands). SDZ PSC 833 and SDZ 280-446 were supplied by Novartis (Basel, Switzerland). LY335979 and vincristine Multidrug-resistant human acute myelogenous leukemia cell lines were obtained by subculturing American Type Culture Collection (ATCC) lines KG1a 27 and HL60 28 in stepwise increased concentrations of daunorubicin and vincristine from 10 to 100 ng/ml (KG1a/200) and from 2 to 65 ng/ml (HL60/130). The parental cells were designated KG1 a/0 and HL60/0, respectively. The human chronic myelogenous K562 (ATCC) cell line 29 designated K562/0, and a multistep selected MDR subline (K562/150) adapted to 150 nm vincristine 30 were provided by Dr Astrid Gruber (Karolinska Hospital, Stockholm, Sweden). The cells were maintained and propagated as previously described. 31 The number of doublings (n) were calculated according to the equation:
where X 0 is the cell count at seeding time point and X is the cell count on day x of the culture.
Cell growth inhibition assay
Approximately 5 × 10 4 cells were plated in 16 mm-diameter wells (Costar Corporation, Cambridge, MA, USA) and grown in 1 ml of drug-free medium for the first 24 h. The wells were then supplemented with the drug or combination of drugs in a certain dose range. At least three replicate cultures were made for each of the dose levels and for untreated controls. The KG1a cells were cultured for 96 h, and the K562 and HL60 cells were cultured for 72 h ensuing two to three doublings. The actual mean numbers of doublings (standard error of the mean in parenthesis) for KG1a/0 were 3.1 (SE 0.2), that for KG1a/200 were 2.7 (SE 0.2), that for K562/0 were 3.3 (SE 0.2), that for K562/150 were 3.1 (SE 0.4), that for HL60/0 were 3.3 (SE 0.1), and that for HL60/130 were 2.0 (SE 0.04). Harvested cells were counted in a Coulter Counter ZM (Coulter Electronics, Luton, UK). Cell numbers were assessed electronically with a lower threshold set at 7.5 m particle diameter to discard cell debris and shrunken (apoptotic) cells. The dose level required for 50% inhibition of cell growth (GI 50 ) was calculated from linear plots of dose vs cell number. The resistance factor (RF) was defined as the ratio between the GI 50 values obtained in the resistant and sensitive cells, respectively. By co-incubation with either SDZ PSC 833, SDZ 280-446 or LY335979 modulation of growth inhibition was assessed. The modulating factor (MF) was defined as the ratio between the GI 50 values of multidrug resistant cells with and without the modulating agent, respectively. Each experiment was performed at least three times.
Flow cytometry Determination of MDR phenotype:
Pgp immunofluorescence was obtained in viable cells by a three-layer staining technique using MRK16 (20 g/ml) and UIC2 (20 g/ml) antibodies to reveal surface epitopes of Pgp as previously described. 31 Determination of MRP required fixation in 0.74% v/v formaldehyde in acetone for 10 s at room temperature to allow staining of a cytoplasmic epitope with MRPr1 (1.7 g/ml) antibody as previously described. 32 Immunofluorescence distributions were generated using a FACScan flow cytometer (Becton Dickinson, San José, CA, USA) tuned to 488 nm laser excitation wavelength. FITC fluorescence of gated populations was collected through a bandpass filter (FL1, bandwidth 515-545 nm). Calculations of logarithmically amplified fluorescence values were performed in arithmetic mode using the CellQuest computer program (Becton Dickinson). Reproducibility was ensured by at least two replicate experiments.
Intracellular accumulation of daunorubicin:
The cells were grown in drug-free medium for 24 h prior to flow cytometric analysis. A FACScan flow cytometer was used to generate daunorubicin fluorescence which provides excitation maximum at 490 nm and emission maximum at 592 nm. 33 The fluorescence was transmitted through a bandpass filter of 564-606 nm (FL2) and logarithmically amplified. Correlated forward angle (a relative measure of cell size) and right angle (a measure of cell granularity) light scatter measurements were generated to exclude dead cells and debris from analyses. Acquired data from 10 000 events were analyzed using Cell Quest. By virtue of daunorubicin fluorescence intracellular accumulation of the drug was measured as fluorescence distributions of cell samples after 1 h incubation at 37°C with 4.4 m daunorubicin alone or in the presence of SDZ PSC 833, SDZ 280-446, or LY335979 at 1 m concentrations. Each experiment was performed three times.
TUNEL assay for detection of apoptotic cells:
Terminal deoxynucleotidyl transferase(TdT)-mediated d-uridine-5Ј-triphosphate(dUTP)-biotin nick end-labeling (TUNEL) utilizes the ability of the enzyme TdT to catalyze binding of deoxynucleotides to 3Ј-OH ends of DNA strand breaks. The method used in this study is based on the method of Gorczyca et al 34 and modified as described. 26 Briefly, the cells were cultured for 48 h in the presence of 1 m SDZ PSC 833, SDZ 280-446 or LY335979, and then 10 6 cells were fixed in 1% ice-cold paraformaldehyde and subsequently in methanol at −20°C before 30 min incubation at 37°C in a TdT solution (Boehringer Mannheim, Mannheim, Germany) which included biotin-labeled dUTP. Subsequently, the cells were incubated on ice with streptavidin-fluorescein isothiocyanate (FITC) for 30 min, and finally counterstained with 5 g/ml propidium iodide (PI) to measure DNA content. Analyses were performed using FACScan and FACSVantage (Becton Dickinson) flow cytometers. FITC green fluorescence represented DNA strand breaks as in apoptosis, and PI red fluorescence represented DNA content. Doublet discrimination and exclusion of debris and clumps were achieved using red fluorescence pulse-width analyses. Each experiment was performed three times.
APO-1/Fas expression:
The IgG2a antibody BMS138 and the IgG2b antibody BMS140 (both Bender MedSystems, Vienna, Austria) were selected as primary APO-1/Fas antibodies. Cell suspensions were washed with PBS/BSA and incubated on ice for 60 min with BMS138 (10 g/ml), BMS140 (10 g/ml), MOUSE IgG2a (25 g/ml), or MOUSE IgG2b (25 g/ml) in PBS/BSA. The second and third layer staining protocols were carried out as described for Pgp detection and followed by flow cytometry as described in 'Determination of MDR phenotype'. Reproducibility was ensured by two replicate experiments.
Cytospin preparations
Cytospin preparations were made by centrifugation of aliquots of approximately 10 5 cells in 300 l RPMI and 300 l fixative (95% methanol and 5% carbowax 1540) at 1000 r.p.m. for 5 min using Shandon Cytospin 2 (Shandon Scientific, Cheshire, UK). Automated Papanicolaou staining was performed in a Jung Autostainer XL (Leica, Germany) as previously described. 26 
Immunoblotting
Cell lines which were to be analyzed for expression of several proteins involved in the regulation of apoptosis were prepared for immunoblotting as follows: 2-3 × 10 6 cells from each cell line, washed once in PBS, were boiled for 5 min in sodium dodecyl sulphate (SDS) sample buffer containing 0.1 mm phenylmethylsulfonylfluoride (PMSF). These were then cooled on ice and frozen at −20°C until use. The proteins and Kaleidoscope molecular weight standards (BioRad, Hercules, CA, USA) were first separated by electrophoresis in 8.0% or 12.0% SDS-polyacrylamide gels. 35 Immunoblotting was done as described previously 36 using the following antibodies: antiBax P-19 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at final concentration 2 g/ml, anti-Bcl-xL S-18 (Santa Cruz Biotechnology) at 2 g/ml, anti-Bcl-2 clone 124 (Dako, Oslo, Norway) at 5 g/ml, anti-p53 Pab 1801 (Calbiochem, Cambridge, MA, USA) at 2.5 g/ml and anti-p-83 34C1 (kindly provided by Dr T Stokke, The Norwegian Radium Hospital, Oslo, Norway) at 1:30 dilution of stock. The amount of p83 was determined on the same blots as a control for gel loading and cell concentration as described previously. 36 An amplified biotin-streptavidin alkaline phosphatase staining procedure (BioRad) was used to detect primary antibodies. Reproducibility was ensured by two replicate experiments.
Statistics
Comparisons of mean values were performed by two-tailed unpaired t tests using Prism software (GraphPad, San Diego, CA, USA). P values Ͻ0.05 were regarded as statistically significant. Summary statistics were reported as means provided with standard errors of the mean (SE) or 95% confidence intervals (CI). Histogram comparisons were performed by Kolmogorov-Smirnov statistics 37 to generate D values ranging between 0 and 1.0 according to the difference between two distributions (higher values indicate greater difference). D values у0.15 were regarded as significant differences between two histograms. 38 
Results
MDR phenotype
The MDR phenotypes were determined by flow cytometric immunofluorescence detection using anti-Pgp (MRK16, UIC2) and anti-MRP (MRPr1) antibodies. The degree of protein expression was determined by the expression factor (EF), which was defined as the ratio between mean fluorescence values for relevant (numerator) and irrelevant (denominator) antibody. To distinguish between wild-type and MDR phenotype a discrimination factor (DF) was defined as the ratio between the EF values for resistant (numerator) and parental (denominator) cells. Using MRK16 the KG1a/200 and K562/150 cells were highly positive for Pgp with EF values of 65.5 and 71.9, respectively. The parental KG1a/0 cells were slightly Pgp-positive (EF = 8.8) and the parental K562/0 cells were completely negative (EF = 0.7). Both the HL60/0 and HL60/130 cells expressed negligible levels of Pgp (EF = 2.9 and 1.6, respectively). In comparison with parental cells the resistant KG1a and K562 variants overexpressed Pgp multifold (DF = 7 and 103, respectively), whereas Pgp expression was not increased in the resistant HL60 variant (DF = 0.6). These results were reproduced using UIC2 which resulted in corresponding DF values (5, 69 and 0.5, respectively). Overexpression of MRP occurred only in the resistant HL60 subline (DF = 5) using MRPr1. Only trace amounts of MRP were detected in the other leukemia cell lines of this study.
Pgp function
Cytotoxic daunorubicin is a known substrate of both Pgp 39 and MRP. 40 Therefore, we assessed Pgp or MRP function in terms of cellular accumulation of daunorubicin using flow cytometry and fluorescence detection in cells that were incubated for 60 min at 37°C with 4.4 m of the drug. Accumulation of daunorubicin was restricted in all the resistant sublines compared to the corresponding wild types (P р 0. 
Cytotoxic effect of the Pgp inhibitors
To study the effect of Pgp inhibition on cell proliferation we performed four replicate experiments measuring cell growth in the three pairs of leukemia cell lines during single-drug treatment with increasing doses of the resistance modulating agents. The growth of the KG1a/200 and K562/150 cells was inhibited in a dose-dependent manner by treatment with nanomolar concentrations of either SDZ PSC 833, SDZ 280-446 or LY335979 (Figure 1 ), whereas the growth of the corresponding parental lines and both sensitive and resistant HL60 lines remained unaffected by equivalent treatment (Figure 2) . The half-maximal growth inhibitory doses for the responsive cells are listed in Table 1 .
Pgp inhibition is associated with apoptosis induction
Previously, we demonstrated by microscopy that exposure of drug resistant KG1a cells to SDZ PSC833 resulted in chromatin condensation and nuclear fragmentation, 26 which are characteristic morphological features of apoptosis. In the present study we measured DNA fragments resulting from apoptosis in cells exposed for 48 h to 1 m of either SDZ PSC 833, SDZ 280-446 or LY335979 using TUNEL assay and flow cytometry. Cellular DNA content was measured simultaneously. The results showed that the KG1a/200 and K562/150 MDR variants were clearly apoptotic as demonstrated by at least a two-fold increase in the FITC-fluorescence signal from dUTP-labeled DNA fragments compared to a neglible increase in the parental cells (Figure 3) .
Furthermore, striking changes in the DNA distribution of KG1a/200 cells occurred after treatment for 48 h with the modulators. In the control cultures the percentages of cells in each cell cycle compartment were as follows: G1 phase 35%, S phase 35% and G2/M phase 30%. In the SDZ PSC 833-treated cultures the G1 phase population was reduced to 4%, the S phase population to 6% and the G2/M phase population increased to 62%, which indicates G2/M arrest. In addition, cells of both higher (18%) and lower (10%) ploidy emerged, the latter representing advanced stages of apoptosis with only remnants of the nuclei left in the cells. Similar results were observed following treatment with SDZ 280-446 and LY335979 as well (Figure 4) , and by using these agents the G2/M populations increased to 65% and 60%, respectively. These populations were shown to consist of true tetraploid cells and not doublets or clumps, by the use of pulse-processed red fluorescence signals, which allowed for doublet discrimination. Correspondingly, microscopic images demonstrated several binucleated cells as well as nuclear fragmentation ( Figure 5 ). The wild-type KG1a cells were not receptive to these changes in cell cycle distribution.
The cell cycle distribution of the resistant K562 cells underwent similar changes as the resistant KG1 a cells after exposure to the three modulators. In particular, the changes induced by LY335979 were pronounced with reduction of the G1 phase population from 49% to 4%, reduction of the S phase population from 19% to 6%, increment of the G2/M phase population from 26% to 42% and emergence of large populations with subdiploid (23%) and polyploid (25%) cells. The cell cycle distribution of the wild-type K562 cells remained unchanged after equivalent treatment.
Expression of proteins involved in apoptosis regulation
Expression of several proteins involved in the regulation of apoptosis, p53, Bcl-xL, Bcl-2, and Bax was assessed using immunoblotting ( Figure 6) . None of the cell lines expressed the apoptosis transcription factor p53, which promotes apoptosis subsequent to DNA damage. 41 On the other hand, expression of the pro-apoptosis Bax protein was moderate in all cell lines. Both the wild type and the MDR variant of KG1a cells expressed high levels of the anti-apoptotic proteins Bcl-2 and Bcl-xL. Both K562 and both HL60 cell types expressed high levels of Bcl-xL. Conversely, Bcl-2 was present at a low level in the K562 cells and basically absent in the HL60 cells. Interestingly, there was no difference in the pattern of expression within each pair of MDR and wild-type cells. Thus, selection for drug resistance did not change the levels of the apoptotic regulators studied in the KG1a, K562 and HL60 cells. Treatment with 1 m SDZ PSC 833 for 48 h did not affect the expression level of these proteins either.
The surface membrane protein APO1/Fas, which is an important transducer of certain apoptotic signals, 42 was measured by flow cytometry and immunofluorescence detection. From these analyses it was evident that APO1/Fas was present in both HL60 cell types, and absent in both K562 cell types, whereas differential expression of APO1/Fas was demonstrated for the wild type and the MDR variant of KG1a cells (Figure 7) . Only the MDR variant was APO1/Fas positive, which might favor a cytotoxic effect of the resistance modulators in these cells.
Discussion
Pgp belongs to the ATP binding cassette (ABC) family of transporter molecules, 43 which also include the MDR-associated protein (MRP). 44 These proteins contribute to MDR by their functional activity as efflux pumps for a wide range of cytotoxic agents. Furthermore, Pgp contributes to transmembrane efflux of certain cytokines 24, 25 which may promote growth of various leukemia cells [45] [46] [47] and provide protection against apoptosis in vitro. 48 Therefore, one possible consequence of Pgp inhibition could be reduction of growth stimuli available to proliferating leukemia cells followed by apoptosis. In the present study we have demonstrated that Pgp overexpression is associated with a growth inhibitory response to the Pgp inhibitors SDZ PSC 833, SDZ 280-446 and LY335979 in the MDR variants of KG1a and K562 leukemia cells. On the other hand, the non-Pgp MDR variant of HL60 cells, which overexpresses MRP, was not receptive to similar growth inhibitory effects. Thus, the cytotoxic effect of the modulators is associated with Pgp in particular and not with MDR in general.
The KG1a and K562 leukemia cells are poorly differentiated and share many characteristics with primitive hematopoietic blast cells. [49] [50] Chaudhary and Roninson 51 have proposed that Pgp in hematopoietic stem cells may be involved in the export of a growth regulatory molecule which was hitherto not identified. The putative role for Pgp in the transmembrane transport of cytokines coincides with an autocrine growth regulation involving a number of cytokines in cell lines derived from patients with AML. It has been demonstrated that leukemic myeloid blast cells generally express high levels of IL1 ␣, IL3, and IL6 receptors, 52 and that blast cells from AML patients both express and produce a number of cytokines including GM-CSF, 53 IL-1, 54 IL-6, 55 IL-9 56 and IL-11. 57 Furthermore, cell proliferation may occur in autocrine loops based on endogenously produced and extracellularly released growth factors. 55, 57 The mechanism behind this kind of cellular signal transduction is unknown, but it is likely that any kind of interference with the processing of vital growth factors, such as transport inhibition by modulating agents, will have a detri- mental effect on cell survival. Correspondingly, withdrawal of the supporting growth factor commonly leads to cell death by apoptosis within a few days in most factor-dependent cell lines, and the apoptotic process can be suppressed by new addition of growth factors. 58 In the present study the TUNEL assay, the DNA distribution analyses and the microscopic images provided evidence that apoptosis contributes substantially to the selective cytotoxicity of the modulating agents studied. The MDR variant of KG1a/200 cells expressed the APO-1/Fas apoptosis transducer, in contrast to the wild type, which suggests that this resistant line is more receptive to apoptosis induction than its parent line. On the other hand, absence of APO-1/Fas does not prevent resistant K562/150 cells from undergoing apoptosis, which indicates that apoptosis induced by SDZ PSC (2N, 4N, 8N) , and the vertical histogram depicts dUTP-FITC incorporation. The arrows demarcated as APO + and the horizontal cut-off lines in the dUTP-FITC histograms indicate apoptotic regions. Treatment of KG1a/200 cells with a modulator results in G2/M arrest, cytokinesis failure, polyploidization and apoptosis, whereas the parental KG1a/0 cells were unaffected. These data were representative for three replicate experiments.
833, SDZ 280-446 and LY335979 is independent of the APO-1/Fas pathway. The BCR-ABL anti-apoptosis gene is a cytogenetic hallmark of chronic myelogenous leukemia (CML), 59 and is constitutively expressed in the CML derived K562 cells, which accordingly, are highly resistant to apoptosis induction by a variety of stimuli. 60, 61 Therefore, it is quite remarkable that the MDR variant of K562 cells also undergoes apoptosis after exposure to nanomolar concentrations of the modulators studied. In addition, the anti-apoptotic regulators Bcl-2 and Bcl-xL contribute to drug resistance of the MDR variants of both KG1a and K562 cells. Both Bcl-2 and Bcl-xL are frequently coexpressed with Pgp in acute myeloblastic leukemia cells and associated with autonomous growth in vitro and poor prognosis of leukemia. 62, 63 The apoptotic promoter p53 64 was not expressed in any of the cell lines studied, which is consistent with the total absence of p53 mRNA and protein expression previously reported for the wild types of KG1a, 65 HL60 66 and K562 67 cells. Although loss of wild-type p53 function is usually associated with resistance to apoptosis, 68,69 the Pgp-rich variants of KG1a and K562 were receptive to apoptosis induction in the present study. Inhibition of Pgp in these cells was also associated with cytokinesis failure as shown by the accumulation of large tetraploid populations and the emergence of binucleated cells using flow cytometry and microscopy, respectively. Thus, our study strongly indicates that overexpression of Pgp is involved in acquisition of cytokinesis failure and apoptosis following exposure to Pgp inhibitors. Cells with a low constitutive level of Pgp appear to be at less risk of these events. Further studies are needed to identify the trigger mechanism(s) and apoptotic pathway(s). Currently, investigations of these are being done using time course flow cytometric DNA analyses and cell sorting of cultures treated with Pgp inhibitory agents.
Development of hypersensitivity to cytotoxic drugs, local anesthetics, narcotic analgesics and calcium antagonists during in vitro selection for drug resistance have previously been reported as collateral sensitivity. [70] [71] [72] Most of these compounds are not substrates of Pgp, and the phenomenon has been associated with alteration of membrane biophysical properties rather than Pgp inhibition. [70] [71] [72] [73] Collateral sensitivity has been demonstrated for drug concentrations in the Figure 4 Continued micromolar range. 72, 74 Conversely, the selective cytotoxicity of the modulators in this study appeared at considerably lower concentrations, which facilitates possible therapeutic exploitation, and resulted specifically in cytokinesis failure and apoptosis induction. The maximally tolerable plasma concentration of PSC 833 in cancer patients is 2.5-3 m, 19 which demonstrates that the concentrations applied in our study are clinically relevant.
The present paper discloses selective cytotoxicity of low doses of the Pgp inhibitory agents SDZ PSC 833, SDZ 280-446 and LY335979. Previously, we have reported a similar effect of high-dose verapamil (GI 50 11.6 m) and a 60-fold lower dose of SDZ PSC 833, which was associated with the MDR phenotype in leukemia cells but not in hepatoma cells. 26 In the present paper we demonstrate that increased MRP expression is not a predisposing factor due to unrestrained growth of MRP expressing HL60 leukemia cells in the presence of the modulators, and efficient growth inhibition of the MDR variants of KGla and K562 leukemia cell lines induced by LY335979 which does not interact with MRP. SDZ PSC 833 and SDZ 280-446 appear to interact with both Pgp and MRP, but the contribution of other transporters cannot be excluded from these experiments. Another MDR-associated ABC transporter, the multispecific organic anion transporter (cMOAT), is only inefficiently inhibited by compounds known to block MRP, 75 and thus represents a less likely target for the modulators studied.
For several reasons it appears that functional restriction of the Pgp efflux pump might be responsible for the particular phenomenon disclosed in this paper. First, the cytotoxicity was conferred by drugs specifically targeted at Pgp interaction. Second, the results were consistent irrespective of structural diversity of the Pgp inhibitory agents. Third, these agents were shown to induce functional inhibition of Pgp at comparable concentrations. Fourth, susceptibility to these agents required Pgp overexpression. Finally, expression of a specific apoptotic regulatory protein did not seem to be the differential factor between receptive and non-receptive cell lines. To further prove the relationship between Pgp and the said phenomenon experiments using homologue cell lines with different Pgp expression levels, cell lines transfected with the MDR1 gene, or cell lines depleted for Pgp by MDR1 antisense treatment are warranted.
In conclusion, our results demonstrate that low-dose treatment of Pgp-rich leukemia cells with different Pgp inhibitory agents results in growth inhibition and cell death by apoptosis. This finding represents a potential therapeutic option that is currently being studied in vivo, and should be considered during the ongoing development of strategies to overcome multidrug resistance. 
Figure 6
Immunoblots demonstrating the distribution of apoptotic proteins in human leukemia wild-type cells and their resistant sublines (KG1a/200, K562/150, HL60/130). Lane A represents a positive control for bax and bcl-2 (normal colonic mucosa). Lane B represents a positive control for bcl-2, bcl-xL and p53 (HTC116 human colon cancer cell line treated with 5FU). Each cell type was examined untreated and after treatment with 1 m SDZ PSC 833 for 48 h. The protein expression appeared to be unaffected by this treatment. The blots were representative for two replicate experiments. 
